Alk-Abello As B Shs New (AKBLF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone, and welcome to this presentation of ALK's Q2 and First Half Year Results. Thank you all for joining us. Let's turn to Slide number two with an introduction to the speakers and the agenda. My name is Piotr Plotnikov, I'm Head of Investor Relations. With me today are CEO, Peter Helling and CFO, Clout Steinsensoglen. Peter and Clout will walk you through the quarterly highlights, markets, product trends and financials. After a brief strategy update, we will turn to the full year outlook. And as usual, we will end the call with a Q and A session. First, I'll hand you over to Peter to the highlights on Slide three. Please go ahead, Peter. Thank you, Peer, and thank you all for taking the time to listen to this call. Alk sustained strong sales momentum in Q2, with double digit sales growth across all regions, driven mainly by tablets and anaphylaxis products. Revenue grew by 18% in local currencies to close to 1,800,000,000, and EBIT increased by 19%. The EBIT margin was unchanged at 25% as gross margin improvements were offset by continued investments in product launches, commercial infrastructure, R and D, AI and other areas. Tablet sales again exceeded DKK 1,000,000,000 and were up 22%. The tablets with the new pediatric indications for Carasax and Etulisax continued to perform well and were increasingly contributing to the inflow of new patients across key markets. We continue to see pediatric indications as a key growth driver for Alk for many years to come. There are still many opportunities in this space. In China, the local Phase III trial of AKARISAX is rapidly approaching the finishing line, with results expected in Q4 this year. If these are positive, we expect to see an important opportunity opening in China, which is the world's largest hausta...